NCT03228667 2026-01-14
QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors
ImmunityBio, Inc.
Phase 2 Active not recruiting
Clinical Trials
38 trialsNCT05481645 2026-01-09
Efficacy and Safety of TQB2450 Injection Combined With Chemotherapy ± Anlotinib Hydrochloride Capsules for Advanced Endometrial Cancer or Sarcoma of Uterus.
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 2 Terminated
NCT05446870 2025-10-01
MK-4830-002
Merck Sharp & Dohme LLC
Phase 2 Completed
NCT05007106 2025-08-14
KEYVIBE-005
Merck Sharp & Dohme LLC
Phase 2 Completed
NCT05325229 2022-10-13
A Study of Docetaxel for Injection (Albumin-bound) in Combination With Bevacizumab in Patients With Ovarian Cancer
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Phase 2 Unknown
NCT05158062 2022-04-26
Pembrolizumab and Bevacizumab With Chemotherapy Followed by Pembrolizumab, Bevacizumab and Olaparib in Recurrent Ovarian Cancer
Saitama Medical University International Medical Center
Phase 2 Unknown
NCT00285415 2021-02-05
A Phase II Evaluation of Docetaxel and Carboplatin Followed by Tumor Volume Directed Pelvic Irradiation
Carilion Clinic
Phase 2 Terminated
NCT00227721 2020-12-02
Gemcitabine and Docetaxel in Treating Patients With Relapsed or Refractory Ovarian Epithelial or Peritoneal Cancer
Barbara Ann Karmanos Cancer Institute
Phase 2 Completed
NCT00214058 2019-11-19
Weekly Carboplatin/Docetaxel for Recurrent Ovarian/Peritoneal Cancer
University of Wisconsin, Madison
Phase 2 Completed
NCT01196429 2019-08-08
Temsirolimus, Carboplatin, and Paclitaxel as First-Line Therapy in Treating Patients With Newly Diagnosed Stage III-IV Clear Cell Ovarian Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00114218 2019-01-08
Gemcitabine and Docetaxel in Treating Patients With Recurrent or Persistent Uterine Cancer
GOG Foundation
Phase 2 Completed
NCT01504256 2018-01-23
CatuNeo
AIO-Studien-gGmbH
Phase 2 Completed
NCT00041093 2018-01-10
Docetaxel in Treating Patients With Persistent or Recurrent Cervical Cancer
GOG Foundation
Phase 2 Completed
NCT00258362 2017-12-28
Carboplatin, Docetaxel, and Radiation Therapy in Treating Patients With Stage III/IV, or Recurrent Endometrial Cancer
Masonic Cancer Center, University of Minnesota
Phase 2 Completed
NCT00354601 2017-08-30
Docetaxel and Capecitabine in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cavity Cancer
Wake Forest University Health Sciences
Phase 2 Terminated
NCT01461746 2017-05-31
Efficacy Study of Chemotherapy Followed by Radiation Therapy to Treat Endometrial Cancer
Asan Medical Center
Phase 2 Unknown
NCT00872989 2016-12-19
S0904: Docetaxel With or Without Vandetanib in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
SWOG Cancer Research Network
Phase 2 Completed
NCT02469116 2016-08-19
Carboplatin Plus Docetaxel With Day 2 Pegylated G-CSF (Neulasta®) in Patients With Advanced Stage Ovarian Carcinoma
Washington University School of Medicine
Phase 2 Terminated
NCT00216112 2016-02-19
Imatinib Mesylate in Combination With Docetaxel for Advanced, Platinum-Refractory Ovarian Cancer
Hoosier Cancer Research Network
Phase 2 Completed
NCT00758732 2015-09-28
Docetaxel/Carboplatin Versus Docetaxel/Caelyx in Pretreated Patients With Ovarian Carcinoma
Hellenic Oncology Research Group
Phase 2 Terminated
NCT00090610 2015-02-25
Second-Line Treatment for Patients With Platinum-Sensitive Ovarian Cancer
Duke University
Phase 2 Completed
NCT00282087 2014-12-01
Adjuvant Chemotherapy for High Risk Uterine Leiomyosarcoma
Sarcoma Alliance for Research through Collaboration
Phase 2 Completed
NCT00183794 2014-05-22
Clinical Trial of Docetaxel in Combination With Gemcitabine in Platinum-Resistant Ovarian Cancer and Primary Peritoneal Carcinoma
University of Southern California
Phase 2 Completed
NCT00085332 2014-01-13
Docetaxel in Treating Patients With Recurrent or Persistent Endometrial Carcinoma (Cancer)
GOG Foundation
Phase 2 Completed
NCT02026921 2014-01-03
A Phase II Study of Docetaxel and Carboplatin in Late Relapse of Ovarian Cancer
Nordic Society of Gynaecological Oncology - Clinical Trials Unit
Phase 2 Completed
NCT00321633 2013-08-26
Carboplatin or Docetaxel in Treating Women With Metastatic Genetic Breast Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00138242 2013-06-26
Docetaxel and Carboplatin in Treating Patients With Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00583622 2013-05-21
Bevacizumab Plus Gemcitabine, Docetaxel, Melphalan, and Carboplatin in Ovarian Cancer Patients
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT00004037 2013-04-11
Docetaxel in Treating Patients With Recurrent or Refractory Ovarian or Primary Peritoneal Cancer
GOG Foundation
Phase 2 Terminated
NCT00004066 2013-03-07
Gemcitabine, Docetaxel, and Filgrastim in Treating Patients With Recurrent or Persistent Leiomyosarcoma or Soft Tissue Sarcoma
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT00257348 2013-02-08
Capecitabine and Docetaxel in Advanced/Recurrent Cervical Cancer
University of California, Irvine
Phase 2 Completed
NCT00069160 2012-10-12
Tariquidar and Docetaxel to Treat Patients With Lung, Ovarian, Renal and Cervical Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT00296816 2012-08-23
TEACO
Sanofi
Phase 2 Completed
NCT00004081 2012-08-13
Docetaxel in Treating Women With Ovarian Epithelial or Primary Peritoneal Cancer
Dana-Farber Cancer Institute
Phase 2 Completed
NCT00231855 2012-04-24
Efficacy Study of Weekly Taxotere and Topotecan for Recurrent Gynecologic (GYN) Cancers
Montefiore Medical Center
Phase 2 Completed
NCT00772863 2009-10-29
Tax-Over
Sanofi
Phase 2 Completed
NCT00178269 2009-05-19
Low-Dose Taxotere® (Docetaxel) With Concurrent Radiotherapy For Localized, Inoperable Carcinoma Of The Uterine Cervix
University of Rochester
Phase 2 Completed
NCT00539669 2007-10-04
TAX + Carboplatin or Cisplatin 1st Line Post-Surgery Ovarian
Sanofi
Phase 2 Completed